Adelaide Robb, MD


Over the past 22 years, Dr. Robb’s research has focused on clinical research in psychopharmacology and, since 1999, on pediatric psychopharmacology. She has been a PI on over 70 clinical trials in pediatric psychopharmacology for a variety of child psychiatric disorders including anxiety, mood, attention deficit hyperactivity disorders, insomnia, and schizophrenia among others. She has been the co-PI on a NIMH study of pediatric bipolar disorder and is the PI on a NICHD study of pediatric bipolar disorder. She was an Associate Clinical Pharmacologist on the Children’s National Medical Center Pediatric Pharmacology Research Unit (PPRU). She has been the principal signatory investigator on two NDA successful submissions to the FDA which led to labeling of the antipsychotics for schizophrenia in adolescents. She is the chair of the American Academy of Child and Adolescent Psychiatry’s Pediatric Psychopharmacology Initiative Committee and serves as the Psychiatric Liaison to the American Academy of Pediatrics’ Committee on Drugs (their pharmacology committee). She has testified before Congress and the FDA on the importance and safety of antidepressants and stimulant medications for children and adolescents with psychiatric disorders. Most recently, she was one of 5 physicians asked to inform the Institute of Medicine on the progress made by the first 15 years of the Best Pharmaceuticals for Children Act and FDA Modernization Act (FDAMA). She reviews for a variety of pediatric and psychiatry journals and has written extensively on pediatric psychopharmacology.